OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
2.160
-0.050 (-2.26%)
At close: Aug 1, 2025, 4:00 PM
2.200
+0.040 (1.85%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Company Description

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.

Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

The company is headquartered in Boulder, Colorado.

OnKure Therapeutics, Inc.
OnKure Therapeutics logo
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees46
CEONicholas Saccomano

Contact Details

Address:
6707 Winchester Circle, Suite 400
Boulder, Colorado 80301
United States
Phone720 307 2892
Websiteonkuretherapeutics.com

Stock Details

Ticker SymbolOKUR
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001637715
ISIN NumberUS68277Q1058
Employer ID47-2309515
SIC Code2834

Key Executives

NamePosition
Dr. Nicholas A. Saccomano Ph.D.President, Chief Executive Officer and Director
Jason A. Leverone CPAChief Financial Officer
Dr. Samuel Agresta M.D., M.P.H.Chief Medical Officer
Dr. Dylan Hartley Ph.D.Chief Scientific Officer
Rogan P. Nunn J.D.General Counsel and Secretary
Dr. James Blake Ph.D.Senior Vice President of Computational Drug Discovery
Dr. Kevin S. Litwiler Ph.D.Senior Vice President of DMPK and Clinical Pharmacology
Dr. Mark L. Boys Ph.D.Senior Vice President of Discovery Chemistry
Roberta AltonSenior Vice President of Clinical Operations

Latest SEC Filings

DateTypeTitle
Jun 26, 20258-KCurrent Report
May 30, 2025SCHEDULE 13D/AFiling
May 29, 2025SCHEDULE 13GFiling
May 28, 2025424B3Prospectus
May 28, 20258-KCurrent Report
May 22, 2025SCHEDULE 13DFiling
May 19, 2025SCHEDULE 13G/AFiling
May 6, 2025424B3Prospectus
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report